Literature DB >> 27071470

Comorbid Medical Conditions in Friedreich Ataxia: Association With Inflammatory Bowel Disease and Growth Hormone Deficiency.

Julianna E Shinnick1, Kimberly Schadt1, Cassandra Strawser1, Nicholas Wilcox1, Susan L Perlman2, George R Wilmot3, Christopher M Gomez4, Katherine D Mathews5, Grace Yoon6, Theresa Zesiewicz7, Chad Hoyle8, S H Subramony9, Eppie M Yiu10, Martin B Delatycki10, Alicia F Brocht11, Jennifer M Farmer1, David R Lynch12.   

Abstract

Friedreich ataxia is a progressive degenerative disease with neurologic and cardiac involvement. This study characterizes comorbid medical conditions in a large cohort of patients with Friedreich ataxia. Patient diagnoses were collected in a large natural history study of 641 subjects. Prevalence of diagnoses in the cohort with Friedreich ataxia was compared with prevalence in the population without Friedreich ataxia. Ten patients (1.6%) had inflammatory bowel disease, 3.5 times more common in this cohort of individuals with Friedreich ataxia than in the general population. Four subjects were growth hormone deficient, reflecting a prevalence in Friedreich ataxia that is 28 times greater than the general population. The present study identifies specific diagnoses not traditionally associated with Friedreich ataxia that are found at higher frequency in this disease. These associations could represent coincidence, shared genetic background, or potentially interactive disease mechanisms with Friedreich ataxia.
© The Author(s) 2016.

Entities:  

Keywords:  Friedreich ataxia; comorbidity; growth hormone deficiency; inflammatory bowel disease

Mesh:

Substances:

Year:  2016        PMID: 27071470     DOI: 10.1177/0883073816643408

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  1 in total

1.  Bone Mineral Density and Current Bone Health Screening Practices in Friedreich's Ataxia.

Authors:  Julia Dunn; Jaclyn Tamaroff; Anna DeDio; Sara Nguyen; Kristin Wade; Nicolette Cilenti; David R Weber; David R Lynch; Shana E McCormack
Journal:  Front Neurosci       Date:  2022-03-14       Impact factor: 5.152

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.